Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 1.00 |
| ▸ | NAE1 | Q13564 | 3/20 | 1.00 |
| ▸ | UBA3 | Q8TBC4 | 2/20 | 1.00 |
| ▸ | UBA1 | P22314 | 1/20 | 1.00 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 1.00 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 1.00 |
| ▸ | RNMT | O43148 | 1/20 | 0.48 |
| ▸ | ADK | P55263 | 3/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23760337 | 1.00 | CA2 (1.00) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297434 | 1.00 | CA2 (1.00) | CA2NAE1UBA3UBA1SAE1 | |
| Hydrochloric Acid SCHEMBL18297575 | 0.99 | CA2 (0.99) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL29484015 | 0.94 | CA2 (0.89) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297457 | 0.94 | CA2 (0.89) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297670 | 0.94 | CA2 (0.88) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297530 | 0.92 | CA2 (1.00) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL29484005 | 0.92 | CA2 (1.00) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297547 | 0.92 | CA2 (0.85) | CA2NAE1UBA3UBA1SAE1 | |
| SCHEMBL18297439 | 0.92 | CA2 (0.85) | CA2NAE1UBA3UBA1SAE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2026-01-15 | — | — | US | claimed |
| EP-4555074-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | Ottawa Hospital Research Institute (CA) | 2025-05-21 | — | — | EP | claimed |
| EP-4532690-A1 | METHODS AND SYSTEMS FOR MODULATING AND MODELING AGING AND NEURODEGENERATION DISEASES | Memorial Sloan-Kettering Cancer Center (US) | 2025-04-09 | — | — | EP | claimed |
| US-20250085272-A1 | METHODS AND SYSTEMS FOR MODULATING AND MODELING AGING AND NEURODEGENERATION DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-03-13 | — | — | US | claimed |
| CN-118416231-A | New use of Neddylination inhibitor in promoting osteoblast differentiation | 首都医科大学 | 2024-08-02 | — | — | CN | claimed |
| US-20240148728-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-05-09 | — | — | US | claimed |
| WO-2024011332-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2024-01-18 | — | — | WO | claimed |
| EP-4297788-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | Nanyang Technological University (SG) | 2024-01-03 | — | — | EP | claimed |
| WO-2023230342-A1 | METHODS AND SYSTEMS FOR MODULATING AND MODELING AGING AND NEURODEGENERATION DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-11-30 | — | — | WO | claimed |
| US-20230218654-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERGLYCEMIA IN TYPE-2 DIABETES | UNIV OKLAHOMA (US) | 2023-07-13 | — | — | US | claimed |
| US-20230172933-A1 | USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-06-08 | — | — | US | claimed |
| CN-115551512-A | Use of compounds or compositions comprising NLRP1 inflammatory body activation inhibitors for the treatment of airway inflammation in humans | 南洋理工大学 | 2022-12-30 | — | — | CN | claimed |
| WO-2022182292-A1 | NOVEL METHOD TO BLOCK INFLAMMATORY CELL DEATH AND IL-1BETA SECRETION CAUSED BY RIBOTOXINS AND UV IRRADIATION USING GENETIC AND CHEMICAL INHIBITORS OF ZAKA AND THE NLRP1 INFLAMMASOME | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-01 | — | — | WO | claimed |
| WO-2022159687-A1 | PHENOTYPIC ASSAY TO IDENTIFY PROTEIN DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022056252-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERGLYCEMIA IN TYPE-2 DIABETES | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2022-03-17 | — | — | WO | claimed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2026-01-15 | — | — | US | disclosed |
| CN-121177307-A | Use of a compound or composition comprising an inhibitor of NLRP1 inflammatory body activation for the treatment of airway inflammation in humans | 南洋理工大学 | 2025-12-23 | — | — | CN | disclosed |
| WO-2022056252-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERGLYCEMIA IN TYPE-2 DIABETES | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015592-A1 | NEDDYLATION-ACTIVATING ENZYME INHIBITORS AS VIRAL SENSITIZERS AND USES THEREOF | NAE1, NEDD8, UBA3 | CA2 1205/4885NAE1 1/4885UBA3 3/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | CA2 1146/4885NAE1 2314/4885UBA3 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.